(Total Views: 533)
Posted On: 06/10/2022 8:56:32 AM
Post# of 154867
Quote:
however we do not know exactly how blocking CCR5 reduces fibrotic scar tissue in NAFLD and Nash liver patients.
We do. The fibrosis develops due to inflammation of the liver causing cell damage. Leronlimab downregulates that inflammation. They've also seen a pattern between NASH, liver cirrhosis and cognitive impairment due to the inflammation.
(10)
(1)
